{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT05176366",
      "OrgStudyIdInfo": {
        "OrgStudyId": "DB-EF-ULCERATIVE-0004"
      },
      "Organization": {
        "OrgFullName": "Direct Biologics, LLC",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis",
      "OfficialTitle": "A Phase I Study of ExoFlo, an ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product, for the Treatment of Medically Refractory Ulcerative Colitis"
    },
    "StatusModule": {
      "StatusVerifiedDate": "January 2022",
      "OverallStatus": "Not yet recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "March 1, 2022",
        "StartDateType": "Anticipated"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "January 1, 2024",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "March 1, 2024",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "November 17, 2021",
      "StudyFirstSubmitQCDate": "December 14, 2021",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "January 4, 2022",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "January 18, 2022",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "January 20, 2022",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Direct Biologics, LLC",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "Yes",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "A Phase I study of ExoFlo, an ex vivo culture-expanded adult allogeneic bone marrow mesenchymal stem cell derived extracellular vesicle product, for the treatment of medically refractory ulcerative colitis"
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Ulcerative Colitis"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "EXOFLO",
          "ULCERATIVE COLITIS"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "10",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "15ml of ExoFlo at Day 0, 2, 4 Week 2, 6, and every 8 weeks after that to week 46",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "IV administration of study agent at Day 0, Day 2, Day 4, Week 2, Week 6 and every 8 weeks thereafter to week 46 (n=5), (total # doses = 10).",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: ExoFlo"
              ]
            }
          },
          {
            "ArmGroupLabel": "15ml of ExoFlo at Day 0, 2, 4 Week 2, 6, and every 4 weeks after that to week 46",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "IV administration of study agent at Day 0, Day 2, Day 4, Week 2, Week 6 and every 4 weeks thereafter to week 46 (n=5), (total # doses = 15).",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: ExoFlo"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "ExoFlo",
            "InterventionDescription": "A Phase I study of ExoFlo, an ex vivo culture-expanded adult allogeneic bone marrow mesenchymal stem cell derived extracellular vesicle product, for the treatment of medically refractory ulcerative colitis",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "15ml of ExoFlo at Day 0, 2, 4 Week 2, 6, and every 4 weeks after that to week 46",
                "15ml of ExoFlo at Day 0, 2, 4 Week 2, 6, and every 8 weeks after that to week 46"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Number of subjects who tolerate intravenous ExoFlo in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.",
            "PrimaryOutcomeDescription": "Number of subjects who tolerate intravenous ExoFlo in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.",
            "PrimaryOutcomeTimeFrame": "70 weeks"
          },
          {
            "PrimaryOutcomeMeasure": "Number of adverse events in subjects who received intravenous ExoFlo in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.",
            "PrimaryOutcomeDescription": "Number of adverse events in subjects who received intravenous ExoFlo in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.",
            "PrimaryOutcomeTimeFrame": "70 weeks"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Number of subjects with improvement with intravenous ExoFlo in inducing clinical remission in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.",
            "SecondaryOutcomeDescription": "Number of subjects with improvement with intravenous ExoFlo in inducing clinical remission in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.",
            "SecondaryOutcomeTimeFrame": "70 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Number of subjects with improvement with intravenous ExoFlo in inducing clinical response in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.",
            "SecondaryOutcomeDescription": "Number of subjects with improvement with intravenous ExoFlo in inducing clinical response in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.",
            "SecondaryOutcomeTimeFrame": "70 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Number of subjects with improving disease-specific health-related quality of life after receiving intravenous ExoFlo.",
            "SecondaryOutcomeDescription": "Number of subjects with improving disease-specific health-related quality of life after receiving intravenous ExoFlo.",
            "SecondaryOutcomeTimeFrame": "70 Weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Measurement of subject's C-reactive protein (CRP)",
            "SecondaryOutcomeDescription": "Measurement of subject's C-reactive protein (CRP)",
            "SecondaryOutcomeTimeFrame": "70 Weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Measurement of subject fecal calprotectin",
            "SecondaryOutcomeDescription": "Measurement of subject fecal calprotectin",
            "SecondaryOutcomeTimeFrame": "70 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Measurement of subject fecal lactoferrin",
            "SecondaryOutcomeDescription": "Measurement of subject fecal lactoferrin",
            "SecondaryOutcomeTimeFrame": "70 weeks"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nMales and Females 18-75 years of age\nUlcerative colitis of at least 6 months duration with medically refractory symptoms\nFailed to have improvement of disease while receiving at least one monoclonal antibody (infliximab, adalimumab, certolizumab, golimumab, vedolizumab, ustekinumab) or tofacitinib for 8 weeks duration prior to enrollment.\nOr has a contra-indication to monoclonal antibodies\nExposure to corticosteroids, 5-ASA drugs, thiopurines, methotrexate, anti-TNF therapy, anti-integrin and anti-interleukin in the past are permitted but a washout period of 8 weeks for any monoclonal antibody is necessary.\nIf receiving conventional immunomodulators (ie, AZA, 6-MP, or MTX), must have been taking them for ≥12 weeks, and on a stable dose for at least 4 weeks.\nIf AZA, 6-MP, or MTX has been recently discontinued, it must have been stopped for atleast 4 weeks.\nIf receiving oral 5-ASA compounds, the dose must have been stable for at least 4 weeks.\nIf receiving oral corticosteroids, the dose must be ≤20 mg/day prednisone or its equivalentand must have been stable for at least 4 weeks.\nIf receiving budesonide, the dose must have been stable for at least 2 weeks.\nIf oral 5-ASA compounds or oral corticosteroids (including budesonide) have been recently discontinued, they must have been stopped for at least 2 weeks.\nThe following medications/therapies must have been discontinued before first administration of study agent:\nTNF-antagonist therapy (e.g. infliximab, etanercept, certolizumab, adalimumab, golimumab, vedolizumab, ustekinumab) for at least 8 weeks.\nCyclosporine, tacrolimus, or sirolimus, for at least 4 weeks.\n6-thioguanine (6-TG) must have been discontinued for at least 4 weeks.\nRectal corticosteroids (ie, corticosteroids [including budesonide] administered to the rectum or sigmoid colon via foam or enema or suppository) for at least 2 weeks.\nRectal 5-ASA compounds (ie, 5-ASAs administered to the rectum or sigmoid colon viafoam or enema or suppository) for at least 2 weeks.\nParenteral corticosteroids for at least 2 weeks.\nTotal parenteral nutrition (TPN) for at least 2 weeks.\nAntibiotics for the treatment of UC (eg, ciprofloxacin, metronidazole, or rifaximin) for atleast 2 weeks.\nNo colonic dysplasia and malignancy as ruled out by colonoscopy within 30 days of MSC delivery\nAbility to comply with protocol\nCompetent and able to provide written informed consent\nStated willingness to comply with all study procedures and availability for the duration of the study\nIf patient is of reproductive capacity, willing to use adequate birth control measures while they are in the study\n\nExclusion Criteria:\n\nInability to give informed consent.\nClinically significant medical conditions within the six months before administration of ExoFlo: e.g. myocardial infarction, active angina, congestive heart failure or other conditions that would, in the opinion of the investigators, compromise the safety of the patient.\nPatients with confirmed HIV, Hepatitis B, or Hepatitis C infections\nAbnormal AST or ALT at screening defined as AST >100 or ALT > 100\nAbnormal basic laboratory values with the following cut-offs:\nAlkaline phosphate >200\nWBC >13\nHemoglobin <7\nPlatelets <50 or > 1 million\neGRF < 60\nHbA1C > 8%\nSubjects with abnormal coagulation studies:\nProthrombin time (PT) > 1.5 times the upper limits of normal\nPartial thromboplastin time (PTT) > 1.5 times the upper limits of normal\nInternational normalized ratio (INR) > 1.5 times the upper limits of normal\nSubjects with hyperbilirubinemia and evidence of liver disease as defined by AST > 100 or ALT > 100 or PT > 1.5 times the upper limits or normal or PT/INR > 1.5 time the upper limits of normal.\nSubjects with abnormal vital signs as defined by any of the following:\nSystolic blood pressure >160 or <90 mmHg\nDiastolic blood pressure >90 or <60 mmHg\nPulse <60 or >105 bpm\nRespiratory Rate <9 and >25 breaths per minute\nTemperature: >100.4 degrees Fahrenheit\nSpO2 : <92%\nHistory of cancer including melanoma (with the exception of localized skin cancers) within 5 years of study enrollment\nInvestigational drug within one year of study enrollment\nPregnant or breast feeding.\nIf patient is of reproductive capacity, unwilling to use adequate birth control measures while they are in the study\nFulminant colitis requiring emergency surgery\nConcurrent active clostridium difficile infection of the colon\nConcurrent CMV infection of the colon\nEvidence of colonic perforation\nMassive hemorrhage from the colon requiring emergent surgery\nCrohn's colitis or indeterminate colitis\nMicroscopic, ischemic or infectious colitis\nNeoplasia of the colon and preoperative biopsy\nPresence of an ostomy\nPrior small bowel resection\nPrevious colonic resection\nColonic stricture that unable to pass an adult colonoscope\nActive or latent tuberculosis\nUnable to wean off corticosteroids\nPatients with extra colonic ulcerative colitis including primary sclerosing cholangitis\nPatients with history of or current evidence of alcohol or drug abuse or dependence, recreational use of illicit drug or prescription medications, or have use of medical marijuana within 90 days of study entry\nPatients with known allergy to local anesthetics\nPatients taking anticoagulant medications (e.g. warfarin, heparin) or clopidogrel (Plavix) to reduce the risk of bleeding/ hemarthrosis\nIndividuals with inherited or acquired hypercoagulable states, history of thromboembolic events or bleeding disorders\nElectrocardiogram demonstrating cardiac arrhythmia, except for sinus tachycardia within the predefined limit of no greater than 105 bpm.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "75 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Heidi Moran",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "800-791-1021",
            "CentralContactEMail": "hmoran@directbioloics.com"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Vikram Sengupta, MD",
            "OverallOfficialAffiliation": "Direct Biologics",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "Undecided"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 21, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000003092",
            "ConditionMeshTerm": "Colitis"
          },
          {
            "ConditionMeshId": "D000003093",
            "ConditionMeshTerm": "Colitis, Ulcerative"
          },
          {
            "ConditionMeshId": "D000014456",
            "ConditionMeshTerm": "Ulcer"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000005759",
            "ConditionAncestorTerm": "Gastroenteritis"
          },
          {
            "ConditionAncestorId": "D000005767",
            "ConditionAncestorTerm": "Gastrointestinal Diseases"
          },
          {
            "ConditionAncestorId": "D000004066",
            "ConditionAncestorTerm": "Digestive System Diseases"
          },
          {
            "ConditionAncestorId": "D000003108",
            "ConditionAncestorTerm": "Colonic Diseases"
          },
          {
            "ConditionAncestorId": "D000007410",
            "ConditionAncestorTerm": "Intestinal Diseases"
          },
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000015212",
            "ConditionAncestorTerm": "Inflammatory Bowel Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M16358",
            "ConditionBrowseLeafName": "Ulcer",
            "ConditionBrowseLeafAsFound": "Ulcerative",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M5472",
            "ConditionBrowseLeafName": "Colitis",
            "ConditionBrowseLeafAsFound": "Colitis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M5473",
            "ConditionBrowseLeafName": "Colitis, Ulcerative",
            "ConditionBrowseLeafAsFound": "Ulcerative Colitis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M8027",
            "ConditionBrowseLeafName": "Gastroenteritis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8035",
            "ConditionBrowseLeafName": "Gastrointestinal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6407",
            "ConditionBrowseLeafName": "Digestive System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5488",
            "ConditionBrowseLeafName": "Colonic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9596",
            "ConditionBrowseLeafName": "Intestinal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M17069",
            "ConditionBrowseLeafName": "Inflammatory Bowel Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC06",
            "ConditionBrowseBranchName": "Digestive System Diseases"
          }
        ]
      }
    }
  }
}